This browser does not support the Video element.
FDA approves new brain cancer treatment pill
FOX 13's Evyn Moon talked with health experts about a new breakthrough brain cancer treatment drug as the FDA has now approved it.
TAMPA, Fla. - The FDA has approved a new drug called Modeyso for the treatment of diffuse midline glioma (DMG), a rare and aggressive brain and spinal cord cancer.
What we know:
DMG impacts about 200 to 300 people in the U.S. annually, mostly children and young adults. The drug is usually taken once a week in pill form, offering an alternative to risky surgeries and radiation treatments.
READ: Dormant cancers can be reawakened by flu, COVID: Study
Dr. Patrick Grogan of Tampa's Moffitt Cancer Center said this is a milestone for brain tumor treatment. Historically, very few drugs have been approved for these types of tumors.
"When you're talking about somebody who's a pediatric patient... these people have a life to live... so it's really cool when we see approvals like this," Grogan said.
MORE: New vaccine designed to help fight colorectal, pancreatic cancer shows promising results: Study
Why you should care:
DMG survival rates are typically less than a year, and treatment options have been extremely limited. Modeyso offers patients not just more time, but potentially better quality of life by reducing the need for invasive procedures.
What's next:
While not a cure, Modeyso aims to slow tumor growth and improve symptoms. Doctors and families are hopeful this breakthrough will pave the way for more treatments in the future.
The Source: Information is based on an interview with Dr. Patrick Grogan at Moffitt Cancer Center.